More than one-fifth of patients using a testosterone gel sold by Auxilium Pharmaceuticals Inc. developed heart problems in a study of mobility-impaired men aged 65 and older.  This product has a similar applciation focus to ASX listed Acrux's efforts. The Auxilium study found that 23 of 106, or 22 percent, of men getting the gel, Testim, had heart-related side effects such as chest pain, heart attack, stroke, or elevated blood pressure, according to a report published today in the New England Journal of Medicine. Of the 103 men who got a placebo, just five, or 5 percent, had similar adverse effects, the researchers at Boston University Medical Center found.

However, the study was with a smaller group and involved a larger dose than is recommended by the drug manufacturer. Considerations in a more complete article are at: http://www.bloomberg.com/news/2010-06-30/testosterone-gel-linked-to-heart-problems-in-frail-older-men-in-study.html

The last 12 months has seen the Auxilium (NASDAQ listed) stock drop over 30%.